18f dpa-714
Small moleculeexperimentalImaging agent
Clinical trial activity
19 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
12
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2009 (NCT01009359)
Timeline
Indications
Studied for
- Alzheimer Disease · Phase 1
- Brain Neoplasms · Phase 2
- Breast Neoplasms · Phase 1
- Carotid Arteries · Phase 1
- Carotid Stenosis · Phase 2
- Cognitive Dysfunction · Phase 1
- Diagnostic Imaging · Phase 1
- Epilepsy, Post-Traumatic · Phase 1
- Fatigue Syndrome, Chronic · Phase 1
- Fibromyalgia · Phase 1
- Healthy Volunteers · Phase 1
- Idiopathic Pulmonary Fibrosis · Phase 1
- Medulloblastoma · Phase 2
- Memory Disorders · Phase 1
- Multiple Sclerosis · Phase 1
- Myocardial Infarction · Phase 1
- Ovarian Neoplasms · Phase 1
- Parkinson Disease · Phase 2
- Positron-Emission Tomography · Early Phase 1
- Severe acute respiratory syndrome-related coronavirus · Early Phase 1
- Triple Negative Breast Neoplasms · Phase 2
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
Loading structure…
SMILES
CCN(CC)C(=O)Cc1c(-c2ccc(OCC[18F])cc2)nn2c(C)cc(C)nc12- Mol. weight
- 397.48 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL451770 ↗
Also known as
- 18f dpa-714
- 18f-dpa-714
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06453915 | Early Phase 1 (Phase 1) | Oct 31, 2024 | University of California, Davis |
| NCT05238961 | Phase 1 | Dec 1, 2023 | University of Alabama, Birmingham |
| NCT05672082 | N/A | Oct 1, 2023 | Center Eugene Marquis |
| NCT05850247 | Phase 2 | Aug 1, 2023 | University of Lyon |
| NCT05656105 | Early Phase 1 (Phase 1) | Jun 1, 2023 | University of Alabama, Birmingham |
| NCT05128903 | Phase 2 | Dec 31, 2021 | St. Jude Children's Hospital |
| NCT04542603 | Phase 1 | Aug 31, 2021 | University of Alabama, Birmingham |
| NCT04364672 | Phase 1 | Jul 1, 2020 | University of Alabama, Birmingham |
| NCT04362644 | Phase 1 | Jun 1, 2020 | University of Alabama, Birmingham |
| NCT04320030 | Phase 2 | Mar 31, 2020 | Institut de Cancerologie de l'Ouest Paul Papin |
| NCT03968445 | Phase 1 | Oct 17, 2019 | University of Alabama, Birmingham |
| NCT03999164 | Phase 1 | Aug 1, 2019 | University of California, Davis |
| NCT03759522 | Phase 1 | Feb 3, 2019 | University of Alabama, Birmingham |
| NCT03230526 | Phase 2 | Apr 20, 2018 | University of Nantes |
| NCT03457493 | Phase 1/Phase 2 (Phase 2) | Mar 22, 2018 | University of Alabama, Birmingham |
| NCT02062099 | Phase 1 | Jan 1, 2014 | François Rabelais University, University of Toulouse |
| NCT02319382 | N/A | Jun 1, 2012 | France Parkinson Association, University of Paris |
| NCT02305264 | N/A | Feb 1, 2012 | University of Paris |
| NCT01009359 | Phase 1 | Oct 1, 2009 | Bayer |
Showing 19 of 19 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Alabama, Birmingham | Academic/Hospital | 8 | 8 | 2 | 2018 |
| University of California, Davis | Academic/Hospital | 2 | 2 | 1 | 2019 |
| University of Paris | Academic/Hospital | 2 | 2 | 1 | 2012 |
| Bayer | For profit | 1 | 1 | 1 | 2009 |
| Center Eugene Marquis | Academic/Hospital | 1 | 1 | 1 | 2023 |
| France Parkinson Association | Academic/Hospital | 1 | 0 | 1 | 2012 |
| François Rabelais University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Institut de Cancerologie de l'Ouest Paul Papin | Academic/Hospital | 1 | 1 | 1 | 2020 |
| St. Jude Children's Hospital | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Lyon | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of Nantes | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Toulouse | Academic/Hospital | 1 | 1 | 1 | 2014 |
12 organizations
Page 1 / 1